2.66 USD
-0.1 (-3.62%)
2.66 USD
0 (0%)
Overall AYTU gets a fundamental rating of 2 out of 10. We evaluated AYTU against 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of AYTU have multiple concerns. AYTU is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year AYTU has reported negative net income.
- AYTU had a negative operating cash flow in the past year.
- AYTU had negative earnings in each of the past 5 years.
- AYTU had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of AYTU (-10.46%) is better than 64.92% of its industry peers.
- AYTU has a Return On Equity of -56.41%. This is comparable to the rest of the industry: AYTU outperforms 49.21% of its industry peers.
- AYTU has a Return On Invested Capital of 1.26%. This is in the better half of the industry: AYTU outperforms 77.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.46% | ||
| ROE | -56.41% | ||
| ROIC | 1.26% |
ROA(3y)-12.29%
ROA(5y)-27.58%
ROE(3y)-57.36%
ROE(5y)-90.09%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With a decent Operating Margin value of 1.85%, AYTU is doing good in the industry, outperforming 77.49% of the companies in the same industry.
- AYTU has a better Gross Margin (67.56%) than 76.44% of its industry peers.
- In the last couple of years the Gross Margin of AYTU has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.85% | ||
| PM (TTM) | N/A | ||
| GM | 67.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.48%
GM growth 5Y-1.06%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), AYTU is destroying value.
- Compared to 1 year ago, AYTU has more shares outstanding
- The number of shares outstanding for AYTU has been increased compared to 5 years ago.
- Compared to 1 year ago, AYTU has a worse debt to assets ratio.
2.2 Solvency
- AYTU has an Altman-Z score of -2.87. This is a bad value and indicates that AYTU is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -2.87, AYTU is doing worse than 60.21% of the companies in the same industry.
- AYTU has a Debt/Equity ratio of 1.09. This is a high value indicating a heavy dependency on external financing.
- AYTU has a worse Debt to Equity ratio (1.09) than 73.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.87 |
ROIC/WACC0.1
WACC12.12%
2.3 Liquidity
- AYTU has a Current Ratio of 1.23. This is a normal value and indicates that AYTU is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Current ratio, with a value of 1.23, AYTU is doing worse than 80.10% of the companies in the same industry.
- A Quick Ratio of 1.08 indicates that AYTU should not have too much problems paying its short term obligations.
- The Quick ratio of AYTU (1.08) is worse than 77.49% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.08 |
3. Growth
3.1 Past
- AYTU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -193.62%.
- Looking at the last year, AYTU shows a very negative growth in Revenue. The Revenue has decreased by -15.61% in the last year.
- AYTU shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.19% yearly.
EPS 1Y (TTM)-193.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.27%
Revenue 1Y (TTM)-15.61%
Revenue growth 3Y-11.79%
Revenue growth 5Y19.19%
Sales Q2Q%-14.38%
3.2 Future
- AYTU is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.77% yearly.
- AYTU is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.87% yearly.
EPS Next Y54.04%
EPS Next 2Y37.81%
EPS Next 3Y29.77%
EPS Next 5YN/A
Revenue Next Year-20.09%
Revenue Next 2Y8.5%
Revenue Next 3Y9.37%
Revenue Next 5Y14.87%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for AYTU. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AYTU. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, AYTU is valued cheaply inside the industry as 99.48% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 1.14 |
4.3 Compensation for Growth
- AYTU's earnings are expected to grow with 29.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.81%
EPS Next 3Y29.77%
5. Dividend
5.1 Amount
- No dividends for AYTU!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
2.66
-0.1 (-3.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)02-10 2026-02-10
Inst Owners35.17%
Inst Owner Change0.39%
Ins Owners4.8%
Ins Owner Change1.1%
Market Cap27.11M
Revenue(TTM)63.70M
Net Income(TTM)-13.07M
Analysts82.22
Price Target9.52 (257.89%)
Short Float %4.8%
Short Ratio6.13
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3758.63%
Min EPS beat(2)-7706.78%
Max EPS beat(2)189.51%
EPS beat(4)3
Avg EPS beat(4)-1821.8%
Min EPS beat(4)-7706.78%
Max EPS beat(4)221.11%
EPS beat(8)6
Avg EPS beat(8)-879.29%
EPS beat(12)8
Avg EPS beat(12)-891.94%
EPS beat(16)10
Avg EPS beat(16)-685.51%
Revenue beat(2)1
Avg Revenue beat(2)-3.69%
Min Revenue beat(2)-17.2%
Max Revenue beat(2)9.83%
Revenue beat(4)3
Avg Revenue beat(4)6.63%
Min Revenue beat(4)-17.2%
Max Revenue beat(4)31.67%
Revenue beat(8)6
Avg Revenue beat(8)5.43%
Revenue beat(12)7
Avg Revenue beat(12)0.63%
Revenue beat(16)9
Avg Revenue beat(16)0.23%
PT rev (1m)1.82%
PT rev (3m)1.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-25%
EPS NY rev (1m)25.97%
EPS NY rev (3m)-34.12%
Revenue NQ rev (1m)-2.66%
Revenue NQ rev (3m)-1.5%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)-11.31%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.43 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.17 | ||
| P/tB | N/A | ||
| EV/EBITDA | 1.14 |
EPS(TTM)-2.76
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.13
OCFYN/A
SpS6.25
BVpS2.27
TBVpS-1.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.46% | ||
| ROE | -56.41% | ||
| ROCE | 2% | ||
| ROIC | 1.26% | ||
| ROICexc | 2.26% | ||
| ROICexgc | N/A | ||
| OM | 1.85% | ||
| PM (TTM) | N/A | ||
| GM | 67.56% | ||
| FCFM | N/A |
ROA(3y)-12.29%
ROA(5y)-27.58%
ROE(3y)-57.36%
ROE(5y)-90.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.48%
GM growth 5Y-1.06%
F-Score3
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.27 | ||
| Cap/Depr | 65.05% | ||
| Cap/Sales | 4.85% | ||
| Interest Coverage | 0.4 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.23 | ||
| Quick Ratio | 1.08 | ||
| Altman-Z | -2.87 |
F-Score3
WACC12.12%
ROIC/WACC0.1
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-193.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-52.27%
EPS Next Y54.04%
EPS Next 2Y37.81%
EPS Next 3Y29.77%
EPS Next 5YN/A
Revenue 1Y (TTM)-15.61%
Revenue growth 3Y-11.79%
Revenue growth 5Y19.19%
Sales Q2Q%-14.38%
Revenue Next Year-20.09%
Revenue Next 2Y8.5%
Revenue Next 3Y9.37%
Revenue Next 5Y14.87%
EBIT growth 1Y177.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-129.64%
EBIT Next 3Y80.53%
EBIT Next 5YN/A
FCF growth 1Y-216.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-135.83%
OCF growth 3YN/A
OCF growth 5YN/A
AYTU BIOPHARMA INC / AYTU FAQ
Can you provide the ChartMill fundamental rating for AYTU BIOPHARMA INC?
ChartMill assigns a fundamental rating of 2 / 10 to AYTU.
Can you provide the valuation status for AYTU BIOPHARMA INC?
ChartMill assigns a valuation rating of 1 / 10 to AYTU BIOPHARMA INC (AYTU). This can be considered as Overvalued.
How profitable is AYTU BIOPHARMA INC (AYTU) stock?
AYTU BIOPHARMA INC (AYTU) has a profitability rating of 3 / 10.
What is the earnings growth outlook for AYTU BIOPHARMA INC?
The Earnings per Share (EPS) of AYTU BIOPHARMA INC (AYTU) is expected to grow by 54.04% in the next year.